Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday
Cytek Biosciences (CTKB) is scheduled to announce its Q4 2025 earnings before market open on Thursday, February 26, 2026, with an expected EPS of $0.02. The company, which specializes in cell analysis solutions, currently has a "Hold" consensus rating from analysts with an average price target of $5.50. Institutional investors hold significant stakes in CTKB, with several firms recently increasing their positions.
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
Cytek Biosciences, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference. Management will provide a hybrid presentation and fireside chat on March 4th. A live and archived webcast of the event will be available on the company's investors section.
Live March 4 Cytek Biosciences talk at TD Cowen health care conference
Cytek Biosciences (Nasdaq: CTKB) is scheduled to participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, in Boston. Management will present in a hybrid format and engage in a fireside chat at 8:10 a.m. PT / 11:10 a.m. ET. A live and archived webcast of the presentation will be available on the company's investor relations website.
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Cytek Biosciences (NASDAQ:CTKB) has experienced a significant 27% drop in its share price over the last month, contributing to a 20% decline over the past year. Despite this slump, the company's price-to-sales (P/S) ratio of 2.7x remains consistent with the broader U.S. Life Sciences industry average of 2.8x. This alignment suggests that investors' opinions on CTKB's valuation match its industry peers, driven by forecasts of average future revenue growth.
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Cytek Biosciences, Inc. (Nasdaq: CTKB) will announce its financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026. Following the release, the company's management will host a webcast and conference call to discuss the results, business developments, and future outlook. The webcast will be available on the "Investors" section of Cytek's website.
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced it will release its financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026. Following the release, the company will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments, and outlook. The webcast will be accessible on the "Investors" section of Cytek's website.
Cytek Biosciences Stock (CTKB) Opinions on Preliminary Q4 and FY2025 Revenue Results
Cytek Biosciences (CTKB) shares surged following the release of strong preliminary Q4 and full-year 2025 revenue figures, indicating substantial growth across all segments. Social media discussions highlight optimism among traders, with attention now turning to future catalysts for sustained performance. The article also details institutional investor activity, government contracts, and analyst ratings, showing a positive outlook with a median price target of $6.25.
New York State Common Retirement Fund Has $1.15 Million Holdings in Cytek Biosciences, Inc. $CTKB
The New York State Common Retirement Fund significantly reduced its stake in Cytek Biosciences (NASDAQ:CTKB) by 84.1% in Q3, now holding 331,190 shares valued at approximately $1.15 million. Despite this, institutional investors collectively own nearly 69.5% of the company's stock, with various funds recently adjusting their positions. Cytek Biosciences currently has a consensus "Hold" rating from analysts with an average price target of $5.50, and its stock trades around $4.46 with a negative P/E ratio.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Analysts
Cytek Biosciences, Inc. (NASDAQ:CTKB) has received a consensus "Hold" rating from analysts, based on reports from seven research firms. The average one-year price target for the stock is $5.50. The company, which specializes in advanced spectral flow cytometry systems, currently trades at $4.93 with a market capitalization of $630.35 million.
Cytek Biosciences (NASDAQ:CTKB) Trading Up 3.2% - Should You Buy?
Cytek Biosciences (NASDAQ:CTKB) shares increased by 3.2% to $5.16, with trading volume 4% above average. The company specializes in spectral flow cytometry systems for single-cell analysis and has a market cap of approximately $660 million, with institutional ownership at nearly 69.5%. Analyst ratings are mixed, leading to an average "Hold" rating and a consensus price target of $5.50.
Cytek Biosciences Data Breach Investigation
Strauss Borrelli PLLC is investigating a data breach at Cytek Biosciences, Inc. that exposed sensitive personal and protected health information. The breach, which occurred around November 1, 2025, involved unauthorized access to Cytek's systems, leading to potential compromise of data including names, Social Security numbers, contact information, and health details. Cytek began notifying impacted individuals on December 22, 2025, and is offering 24 months of complimentary credit monitoring services.
Institutional owners may take dramatic actions as Cytek Biosciences, Inc.'s (NASDAQ:CTKB) recent 6.9% drop adds to one-year losses
Institutional investors hold a significant 52% stake in Cytek Biosciences, Inc. (NASDAQ:CTKB), making them influential in the company's stock performance. A recent 6.9% drop, contributing to a 1.1% one-year loss for stockholders, could lead these institutions to sell, potentially impacting individual investors. BlackRock, Inc. is the largest shareholder, and the top 10 shareholders control over half the company, while insiders own shares worth US$64 million.
Institutional owners may take dramatic actions as Cytek Biosciences, Inc.'s (NASDAQ:CTKB) recent 6.9% drop adds to one-year losses
Institutional investors own 52% of Cytek Biosciences (NASDAQ:CTKB), making them a powerful force in the company's stock performance. A recent 6.9% stock drop added to a 1.1% one-year loss, which could lead institutions to sell shares, impacting individual investors. The top 10 shareholders hold 50% of the business, with BlackRock, Inc. being the largest at 13%.
Cytek Biosciences Preliminary Q4 Revenue Up 8%
Cytek Biosciences announced preliminary revenue for Q4 2025 is expected to be approximately $62 million, an 8% increase compared to Q4 2024. For the full year 2025, total revenue is projected to be around $201 million. Following this announcement, shares of Cytek Biosciences rose 9.7% in pre-market trading.
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Cytek Biosciences has announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025, expecting total revenue of approximately $201 million for the full year. The company anticipates fourth-quarter revenue of around $62 million, marking an 8% growth compared to Q4 2024, driven by strong performance in Services, Reagents, and Asia Pacific instrument revenue, alongside improved instrument sales in the US and EMEA. Cytek will also present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Cytek Biosciences announced preliminary, unaudited revenue results for Q4 and the full year 2025, expecting total revenue of approximately $201 million for the year and $62 million for Q4. The company noted an 8% growth in Q4 2025 revenue compared to Q4 2024, attributed to strong performance in Services, Reagents, Asia Pacific instrument revenue, and improved instrument sales growth in the US and EMEA. Cytek will also present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Rating of "Hold" from Analysts
Cytek Biosciences (NASDAQ:CTKB) has received a consensus "Hold" rating from eight analysts, with an average one-year price target of $5.50. Institutional investors significantly own 69.46% of the company, with notable increases in positions from firms like Topline Capital and Millennium Management. The company's shares are currently trading around $5.45, backed by a negative P/E ratio and recent earnings of $0.04 per share, with future fiscal year projections at -$0.06 EPS.
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt In A Risky Way?
This article examines the debt usage of Cytek Biosciences (NASDAQ:CTKB), noting its relatively low net debt position compared to its market capitalization. It highlights the importance of strong earnings before interest and tax (EBIT) generation to service this debt and suggests that while the current debt level may be manageable, investors should monitor its financial health, especially cash flow. The company's recent loss and negative free cash flow are presented as points of concern for future debt sustainability.
Cytek Biosciences webinar explores lung cell communication advances
Cytek Biosciences is hosting a webinar featuring Dr. Anukul Shenoy, who will present research on how lung epithelial cells and CD4+ T cells communicate, influencing their function and location during homeostatic bacterial inhalation. This research could significantly advance our understanding of cellular interactions, potentially leading to new therapeutic strategies.
Cytek Biosciences Data Breach Lawsuit Investigation
Shamis & Gentile P.A. is investigating a data breach at Cytek Biosciences Inc. that occurred in December 2025, potentially exposing sensitive personal information of individuals. If affected, individuals may be entitled to compensation and should review their options, including enrolling in credit monitoring and considering a class action lawsuit. The breach potentially exposed names, contact information, Social Security numbers, driver's licenses, health information, and financial data.
Cytek Biosciences Data Breach Exposes Social Security Numbers
Cytek Biosciences disclosed a data breach on December 22, 2025, affecting an undisclosed number of individuals, including eight Massachusetts residents. The breach exposed a wide range of sensitive personal and health information, such as names, Social Security numbers, financial data, and medical records. In response, Cytek Biosciences is offering 24 months of free identity protection services through Experian IdentityWorks and has set up a dedicated helpline for affected individuals.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Recommendation of "Hold" by Brokerages
Seven brokerages have issued a consensus "Hold" rating for Cytek Biosciences, Inc. (NASDAQ:CTKB), with an average 12-month price target of $5.30. The company recently traded near $4.70, has a market capitalization of $600.9 million, and reported $0.04 quarterly EPS on $40.48 million revenue. Institutional investors hold approximately 69.46% of the stock, with several increasing their stakes.
Brown Capital Management LLC Has $24.17 Million Stock Position in Cytek Biosciences, Inc. $CTKB
Brown Capital Management LLC recently trimmed its stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 4.7% in the second quarter, ending with 7,109,995 shares valued at approximately $24.17 million. Despite the reduction, the firm still holds about 5.59% of the company. Other institutional investors have shown mixed activity, with some increasing their positions and others purchasing new stakes in Cytek Biosciences, which currently trades around $5.20 and has an average analyst rating of "Hold."
Institutional Owners May Consider Drastic Measures as Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Recent US$58m Drop Adds to Long-term Losses
Institutional investors hold a significant 52% ownership in Cytek Biosciences, Inc. (NASDAQ:CTKB), making their decisions crucial for the stock's performance. The company recently experienced an 8.0% share price drop, contributing to a 20% loss over the past 12 months, which may prompt institutions to consider selling, potentially impacting individual investors negatively. Key shareholders include BlackRock, Inc., The Vanguard Group, Inc., and Topline Capital Management, LLC, while insiders own 4.2% and the general public holds 28%.
Revenues Tell The Story For Cytek Biosciences, Inc. (NASDAQ:CTKB) As Its Stock Soars 43%
Cytek Biosciences' stock has recently surged by 43%, though its share price is still down 10% over the last year. The company's price-to-sales (P/S) ratio of 3.8x is comparable to the industry median. While recent revenue has declined, analysts predict future growth aligning with the broader Life Sciences industry, suggesting its P/S is reasonable given these expectations.
Cytek Biosciences (CTKB): Evaluating Valuation After TIME's Growth Leaders 2026 Recognition
Cytek Biosciences (CTKB) has gained significant attention after being recognized on TIME's 2026 list of America's Growth Leaders, leading to a 39% surge in its share price over the last month. Despite this recent momentum, a popular narrative suggests the stock is currently 7% overvalued, with a fair value set at $5.13 against its closing price of $5.50. This valuation is based on strong growth assumptions and potential profit margin transformation, although risks like ongoing weak instrument sales and competition could impact its future performance.
Can Cytek Biosciences' (CTKB) Steady Outlook Offset Its Shift to Losses?
Cytek Biosciences (CTKB) recently reported Q3 2025 earnings with increased revenue but a net loss, a shift from prior year's income. Despite this, the company reaffirmed its full-year revenue guidance, suggesting management's confidence even amid near-term uncertainties in capital equipment spending. While the revenue outlook provides a benchmark, investors are cautioned about persistent net losses and pressure on margins.
Cytek Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary
Cytek Biosciences Inc (CTKB) reported an adjusted loss of 4 cents per share for the quarter ended September 30, beating the average analyst expectation of a 5-cent loss. Revenue for the quarter rose by 1.5% to $52.29 million, surpassing analyst estimates. Despite a quarterly loss of $5.48 million, the company's shares have seen a 12.7% rise this quarter, though they are down 39.8% year-to-date.
Earnings call transcript: Cytek Biosciences Q3 2025 sees revenue rise, stock steady
Cytek Biosciences reported mixed Q3 2025 results, with revenue exceeding expectations at $52.3 million but earnings per share missing forecasts with a loss of $0.04. Despite the EPS miss, the stock saw a 2.56% increase in aftermarket trading, driven by strong revenue performance and a solid cash position. The company reaffirmed its full-year 2025 revenue outlook while focusing on market expansion and innovation.
Cytek Biosciences Named to TIME's 2026 America's Growth Leaders List
Cytek Biosciences, a leader in spectral flow cytometry, has been recognized on TIME’s inaugural 2026 America’s Growth Leaders list. This distinction, in partnership with Statista, honors publicly listed U.S. companies that have demonstrated exceptional growth, financial stability, and stock performance over the past five years. Cytek's CEO emphasized the company's commitment to innovation and accessibility in high-parameter cell analysis, contributing significantly to advancements in fields like cancer research and gene therapies.
TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026
Cytek Biosciences (Nasdaq: CTKB) has been named one of TIME’s America’s Growth Leaders of 2026, a recognition presented in partnership with Statista. This accolade highlights Cytek's strong financial foundation, business expansion, and continued success in developing innovative, high-parameter cell analysis solutions. The company's Full Spectrum Profiling™ (FSP®) technology is noted for advancing research in areas like cancer, cell and gene therapies, vaccines, and emerging diseases, empowering laboratories globally.
TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026
Cytek Biosciences has been named one of TIME's America's Growth Leaders of 2026, an acknowledgment presented in partnership with Statista. This recognition highlights Cytek's notable growth, financial stability, and stock performance over the last five years, positioning it among top-performing publicly listed companies in the U.S. The company attributes this achievement to its dedication to making high-parameter cell analysis accessible and its contributions to scientific and health advancements through its Full Spectrum Profiling™ (FSP®) technology.
Piper Sandler Maintains Cytek Biosciences (CTKB) Overweight Recommendation
Piper Sandler has reaffirmed its "Overweight" recommendation for Cytek Biosciences (CTKB). Analysts predict an average one-year price target of $5.23 per share, suggesting a potential 10.05% upside from its current price. Institutional ownership data indicates a slight decrease in the number of funds holding CTKB, but a notable increase in several key institutional positions.
Cytek Biosciences, Inc. SEC 10-Q Report
Cytek Biosciences, Inc. (CTKB) has released its Form 10-Q report for the third quarter of 2025, detailing its financial performance and operational achievements. The company reported total revenue of $52.3 million but saw a decline in net income to $(5.5) million, primarily due to increased operating expenses. Despite financial challenges, Cytek continues to innovate with its FSP technology, including new product launches, and aims to expand its market presence globally.
Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced its participation in several upcoming investor conferences in November and December 2025. These include the UBS Global Healthcare Conference, Stephens NASH25 Investment Conference, and Piper Sandler 37th Annual Healthcare Conference, where the company will engage in investor 1x1 meetings and fireside chats. Webcasts for the Stephens and Piper Sandler events will be available on the company's investor relations website.
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) reported a Q3 loss of $0.01 per share, which missed the Zacks Consensus Estimate of $0.01 but beat revenue expectations with $52.29 million. Despite mixed earnings outlook and underperforming the market year-to-date, the company holds a Zacks Rank #3 (Hold), suggesting it's expected to perform in line with the market. Investors are watching for future estimate revisions and industry performance.
Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
Cytek Biosciences is expanding access to flow cytometry technology by launching a two-part research initiative with the International Society for Advancement of Cytometry (ISAC). This initiative includes awarding a three-laser Cytek Northern Lights™ flow cytometer and establishing a grant program to fund research projects. These efforts aim to support scientific research globally, especially in under-resourced labs, amidst tightened research funding.
Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025
Cytek Biosciences announced it will report its third-quarter 2025 financial results after market close on Wednesday, November 5, 2025. The company will host a webcast conference call on the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results, business developments, and outlook. Cytek Biosciences is a cell analysis solutions company known for its Full Spectrum Profiling™ (FSP ® ) technology.
Cytek Biosciences to Release Third Quarter 2025 Financial Results on November 5, 2025
Cytek Biosciences, Inc. announced it will release its third-quarter 2025 financial results on November 5, 2025, after market close, followed by a conference call to discuss the results and business developments. The company, known for its Full Spectrum Profiling™ technology in cell analysis, will provide updates on its financial performance and outlook. The article also includes details on recent insider trading, hedge fund activity, and analyst ratings for CTKB stock.
Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced it will report its third-quarter 2025 financial results after market close on Wednesday, November 5, 2025. The company will also host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments, and outlook.
Cytek® Biosciences Expands European Presence with New Facility in - The National Law Review
Cytek Biosciences has expanded its European operations with a new facility in Amsterdam, increasing its footprint by over 40% to meet growing demand for its cell analysis solutions. The new site includes a dedicated customer service and training center, and in-housed warehouse operations for its reagent business. This expansion aims to enhance organizational agility, improve operational efficiency, and accelerate turnaround times for customers across the EMEA region.
Cytek Biosciences relocates European HQ to Amsterdam’s life sciences district - TradingView
Cytek Biosciences Inc. (CTKB) has announced the relocation of its European headquarters to Amsterdam's life sciences district. This move signifies a strategic decision for the company regarding its operations in Europe.
Cytek Biosciences Relocates European Headquarters to New Facility in Amsterdam - MarketScreener
Cytek Biosciences has announced the relocation of its European headquarters to a new facility in Amsterdam. This move is detailed in an article published on Marketscreener. The company's stock, CTKB, is currently trading at $4.060 USD with recent news updates regarding the relocation and other corporate activities.
Cytek Biosciences Relocates European Headquarters to Amsterdam, Expanding Operations and Customer Support - Quiver Quantitative
Cytek Biosciences has relocated and expanded its European headquarters to Amsterdam, increasing its operational footprint by over 40% to enhance regional operations and customer service in the EMEA region. The new facility includes a dedicated customer service and training center with a fully functional lab for hands-on training with their Full Spectrum Profiling™ technology. This strategic move underscores the growing importance of Cytek's reagent business and aims to improve operational oversight, efficiency, and service delivery for researchers and clinicians.
Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth
Cytek Biosciences, Inc. (Nasdaq: CTKB) has announced the relocation of its European headquarters to a new, larger facility in Amsterdam's Life Sciences District. This expansion includes increased office and warehouse space, a dedicated customer service and training center, and in-house warehouse operations for its reagent business. The move aims to strengthen Cytek's presence in the EMEA region and enhance services, training, and operational efficiency for its customers.
Cytek Biosciences Expands European Presence With New Facility in Amsterdam to Better Serve Customers and Drive Growth - 富途牛牛
Cytek Biosciences has expanded its European operations by relocating its headquarters to a new, larger facility in Amsterdam's Life Sciences District. This expansion includes a dedicated customer service and training center with fully functional lab environments, and an in-house warehouse for its reagent business. The move aims to strengthen Cytek's presence in the EMEA region and enhance its ability to deliver solutions, training, and support to researchers and clinicians.
40% Larger Footprint: Cytek Biosciences Opens Amsterdam EU HQ with Training Center & In‑House Warehouse - Stock Titan
Cytek Biosciences (Nasdaq: CTKB) has relocated its European headquarters to a new, 40% larger facility in Amsterdam's Life Sciences District, effective October 15, 2025. This expansion includes offices, an enlarged in-house warehouse, and a dedicated customer service and training center with a fully functional lab for their Full Spectrum Profiling™ (FSP®) technology. The move aims to enhance service, improve quality control, operational agility, and turnaround times across EMEA, driven significantly by the strong performance of its reagent business.
Cytek Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth - MarketScreener
Cytek Biosciences, Inc. has expanded its European presence by relocating its headquarters to a larger facility in Amsterdam's Life Sciences District. This new facility includes a dedicated customer service and training center with fully functional labs, aiming to enhance support for researchers and clinicians. The expansion also strengthens the company's reagent business by bringing warehouse operations in-house, improving efficiency and quality control.
Cytek Biosciences, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Cytek Biosciences, Inc. has undergone a stock evaluation revision, reflecting mixed technical signals and struggles against the S&P 500. The stock closed at $3.94 with significant year-to-date and past year declines, presenting a volatile market dynamic. Technical indicators like MACD and Bollinger Bands show mixed bullish and bearish trends across different timeframes.
Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q’s Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control
Cellares has partnered with five technology providers—Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences, and AltemisLab—to enhance its Cell Q automated quality control platform. This collaboration aims to meet the demand for commercial-scale cell therapy quality control by improving high-throughput sample prep, liquid handling verification, flow cytometry, and sample tracking. The Cell Q platform, designed to match the throughput of Cellares' Cell Shuttle, will present its first performance data at the 10th CAR-TCR Summit on September 25, 2025.
